2.1
Eplontersen (Wainzua, AstraZeneca) is indicated for 'treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with stage 1 and 2 polyneuropathy'.
2 Information about eplontersen
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for eplontersen (PDF only).
Price
2.3
The list price is £31,954.12 for a 45‑mg vial (excluding VAT; company submission). The annual cost is £383,449.44 based on monthly injections.
2.4
The company has a commercial arrangement. This makes eplontersen available to the NHS with a discount. The size of the discount is commercial in confidence.